| | Author, Year, Country | Diagnostic criteria | Experimental group | Control group | Outcomes | | Sample size (in each group) | Gender (M/F) | Age (years) | Course of disease | Intervention | Treatment duration | Sample size | Gender (M/F) | Age (years) | Course of disease | Intervention | Treatment duration | | Mean | Mean | Main acupoints | Duration of acupuncture | Acupuncture frequency | Medication frequency | Total period | Mean | Mean | Medication frequency | Total period |
| | Cao 2019, China | Diagnosis of chronic UC | 49 | 25/24 | 28–75 | NR | MA | RN12, RN4, DU1, ST25, BL25 | 20 min | Q.d | NR | 2 w | 49 | 26/23 | 30–75 | NR | Metronidazole + SASP | Metronidazole: 0.2 g p.o. T.i.d; SASP: 0.2 g p.o. T.i.d | 2 w | ER, AR | | 41.4 ± 12.8 | NR | 40.6 ± 13.2 | NR |
| | Ge 2012, China | Clinical diagnosis and treatment guide | 30 | 31/29 (tot) | 19–58 (tot) | 2 m–7 y (tot) | EA + SASP | ST25, RN6, RN4, ST37, SP6, LR3; BL18, BL20, BL25, BL23, BL32 (alternate) | 60 min | Q.d | The first month: 0.5 g p.o. Q.i.d; the next month: 1.5 g/d | 2 m | 30 | 31/29 (tot) | 19–58 (tot) | 2 m–7 y (tot) | SASP | The first month: 0.5 g p.o. Q.i.d; the next month: 1.5 g/d | 2 m | AR | | 31.7 ± 4.5 (tot) | (3.8 ± 2.1) y (tot) | 31.7 ± 4.5 (tot) | (3.8 ± 2.1) y (tot) |
| | Ge 2014, China | Clinical diagnosis and treatment guide | 31 | 16/15 | 26–71 | 4 m–7 y | EA + SASP | BL18, BL20, BL25, BL23, BL32, ST25, RN6, RN4, ST37, SP6, LR3 (alternate) | 60 min | Q.d | The first month: 1 g p.o. Q.i.d; the next month: 2 g/d | 2 m | 31 | 17/14 | 25–73 | 5 m–8 y | SASP | The first month: 1 g p.o. Q.i.d; the next month: 2 g/d | 2m | ER, AR, ACTH | | 35.6 ± 7.5 | (3.7 ± 2.8) y | 38.4 ± 7.8 | (4.0 ± 2.5) y |
| | Ge 2015, China | Clinical diagnosis and treatment guide | 25 | 27/23 (tot) | 27–71 (tot) | 5 m–8 y (tot) | EA + SASP | BL18, BL23, BL20, BL25, BL32, ST25, ST37, RN4, RN6, LR3, SP6 (alternate) | 60 min | Q.d | The first month: 1 g p.o. Q.i.d; the next month: 2 g/d | 2 m | 25 | 27/23 (tot) | 27–71 (tot) | 5 m–8 y (tot) | SASP | The first month: 1 g p.o. Q.i.d; the next month: 2 g/d | 2m | ER, AR | | 38.5 ± 6.5 (tot) | (4.1 ± 2.7) y (tot) | 38.5 ± 6.5 (tot) | (4.1 ± 2.7) y (tot) |
| | Lin 2020, China | Diagnosis of chronic UC | 30 | 8/22 | 21–77 | 3 m–13 y | EA | RN12, ST36, ST37, LI11, BL23, BL25 | 40 min | Q.o.d | NR | 30 d | 30 | 11/19 | 20–73 | 3 m–15 y | Diphenoxylate Co. + norfloxacin + berberine Co | Diphenoxylate Co.: 2#p.o. T.i.d, norfloxacin: 0.2 g 2#p.o. T.i.d,; berberine: 3#p.o. T.i.d | 30 d | ER, SE | | NR | NR | NR | NR |
| | Liu 2016, China | Diagnosis of chronic UC | 62 | 29/33 | 23–76 | (9–19) m | MA | RN4, RN6, ST25, BL25, DU1 | 10–30 min | Q.o.d | NR | NR | 62 | 30/32 | 24–74 | (9–20) m | Metronidazole + SASP | Metronidazole: 2#-3#，T.i.d p.o. SASP: 2-3 g/d T.i.d p.o. | NR | ER, AR | | 50.67 ± 6.82 | (13.63 ± 5.16) m | 51.14 ± 5.46 | (14.10 ± 5.22) m |
| | Luan 2016, China | Diagnosis of chronic UC | 25 | 13/12 | 26–42 | NR | MA | SP4, KI3, ST36, RN4, ST25，BL16, BL20, BL21, BL22, BL25; DU2, DU6 | 30 min | Q.d | NR | 8 w | 25 | 14/11 | 23–43 | NR | Mesalazine | 1 g p.o. Q.i.d | 8 w | ER, AR | | 34 ± 5.75 | NR | 31.28 ± 6.13 | NR |
| | Luan 2020, China | Diagnosis of chronic UC | 75 | 40/35 | 24–76 | (9–17) m | MA | ST25, RN4, RN6, BL25 | 30 min | Q.d | NR | NR | 75 | 45/30 | 25–75 | (9–18) m | Metronidazole + SASP | Metronidazole: 0.2 g p.o. T.i.d,; SASP: 2.0 g p.o. T.i.d | NR | ER | | NR | NR | NR | NR |
| | Pang 2019, China | Consensus opinions on the diagnosis and treatment of inflammatory bowel disease | 30 | 16/14 | 20–67 | (4–68) m | MA + mesalazine | BL31, BL32, BL33, BL34 | 30 min | Q.o.d | 1.0 g p.o. Q.i.d | 1 m | 30 | 19/11 | 20–64 | (4–66) m | Mesalazine | 1.0 g p.o. Q.i.d | 1 m | ER, baron score; serum TNF-α, IL-6, IL-8, IL-10 | | 41.63 ± 12.86 | (36.90 ± 20.94) m | 43.33 ± 15.51 | (38.03 ± 18.42) m | | Sun 2015, China | Consensus opinions on the diagnosis and treatment of inflammatory bowel disease | 32 | 16/16 | 28–60 | ≤8 y | MA + mesalazine | RN3, RN4, RN6; ST25, SP15; BL25; ST36, ST37, SP6; LR3 | 30 min | NR | 1 g p.o. Q.i.d | 2 m | 32 | 18/14 | 24–57 | ≤7 y | Mesalazine | 1 g p.o. Q.i.d | 2 m | ER, T cell subsets | | Wang 2017, China | World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010 | 35 | NR | NR | NR | MA | RN12, ST25, RN6, ST36, SP6 | 30 min | Q.d | NR | 4 w | 35 | NR | NR | NR | SASP | 500 mg p.o. Q.i.d | 4 w | ER, serum IL-6, IL-8, AR |
| | Wang 2020, China | Diagnosis of chronic UC | 39 | 22/17 | 44–54 | NR | MA + aminosalicylic acid | Sibian, ST25, RN4, RN6 | 15–20 min | NR | 1-2#p.o. T.i.d | NR | 39 | 25/14 | 45–61 | NR | Aminosalicylic acid | 1-2#p.o. T.i.d | NR | Mayo score, AR | | 49.27 ± 5.17 | NR | 53.13 ± 8.23 | NR |
| | Wang 2021, China | Consensus opinions on the diagnosis and treatment of inflammatory bowel disease | 98 | 46/52 | − | NR | MA + mesalazine + flupentixton melitoxin | Guiyan (LU11, SP1） | 20 min | NR | Mesalazine, 500 g p.o. T.i.d; flupentixton melitoxin (0.5 mg/10 mg), 1#p.o. Q.d | 1 m | 98 | 44/54 | NR | NR | Mesalazine + flupentixton melitoxin | Mesalazine: 500 g p.o. T.i.d; flupentixton melitoxin (0. 5 mg/10 mg): 1#p.o. q.d. | 1 m | ER, baron score, HADS scale, serum MMP –9, TMAO | | 37.32 ± 8.16 | (13.14 ± 5.46) m | 38.16 ± 9.52 | (13.62 ± 6.58) m |
| | Yan 2019, China | Diagnosis of chronic UC | 41 | 25/16 | 24–61 | NR | MA | ST25, LR13, LI4, BL20, ST37 | 30 min | Q.d | NR | 30 d | 41 | 27/14 | 25–63 | NR | Mesalazine | 1 g p.o. Q.i.d | 30 d | ER | | 42.5 ± 4.4 | NR | 44.3 ± 4.6 | NR |
| | Zhang 2018, China | Diagnosis of chronic UC | 50 | 26/24 | 35–69 | 10 d–3 y | MA | RN4, RN6, ST25, DU1, BL25 | 10–30 min | Q.o.d | NR | 30 d | 50 | 30/20 | 34–70 | 9 d–2 y | Metronidazole | 0.2 g p.o. T.i.d | 30 d | ER, AR | | 45.6 ± 0.01 | (2.1 ± 0.01) y | 46.5 ± 0.5 | (1.2 ± 0.01) y | | Zhao 2020, China | Diagnosis of chronic UC | 75 | 35/40 | NR | NR | MA | ST36, ST37, ST25, DU1, ST36, SP6, ST25 | NR | Q.d | NR | 10 d | 75 | 42/33 | NR | NR | Mesalazine | p.o. T.i.d | 10 d | ER, AR, SF-36 |
|
|
